Quick Answer
Indaptus Therapeutics, Inc. reported Diluted EPS of $21.58 per share (loss) for fiscal year 2025.
Indaptus Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$21.58 | +52.0% |
| 2024 | -$44.96 | -2356.8% |
| 2023 | -$1.83 | -5.8% |
| 2022 | -$1.73 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.98 | +67.0% | +67.2% |
| June 30, 2025 | -$9.09 | +30.9% | -2740.6% |
| March 31, 2025 | -$0.32 | +28.9% | +96.5% |
| September 30, 2024 | -$9.04 | -1823.4% | +31.3% |
| June 30, 2024 | -$13.16 | -3274.4% | -2824.4% |
| March 31, 2024 | -$0.45 | +11.8% | +4.3% |
| September 30, 2023 | -$0.47 | -11.9% | -20.5% |
| June 30, 2023 | -$0.39 | +15.2% | +23.5% |
- Indaptus Therapeutics, Inc. showed an increase of +52.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, Indaptus Therapeutics, Inc.’s diluted eps has declined by 1147.4% (from $1.73 per share (loss) to $21.58 per share (loss)).
- The most recent figure is from Indaptus Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: